-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the 2022 edition of the "China Expert Consensus on Risk Assessment and Management of Panvascular Disease in Patients with Type 2 Diabetes" (hereinafter referred to as the consensus) was released
in four major magazines at the same time: Chinese Journal of Diabetes, Chinese Journal of Health Management, Chinese Journal of Circulation and Cardiology Plus.
The consensus is led by the Cardiovascular Medicine Branch of the Chinese Medical Doctor Association to organize domestic authoritative scholars in five major fields, including cardiovascular disease, endocrinology, nephrology, neurology and health management, combined with important scientific evidence in this field and the practical experience of clinicians at home and abroad
.
The consensus content covers the epidemiological characteristics, pathophysiological mechanism, multidisciplinary collaborative diagnosis and treatment, risk assessment and management of panvascular disease in patients with T2DM, and a total of 21 recommendations can provide systematic and standardized guidance for
the risk assessment and management of panvascular disease in patients with type 2 diabetes.
The consensus applies to doctors
in internal medicine, surgery, general medicine and physical examination who are engaged in clinical work.
Expert Consensus on Risk Assessment and Management of Panvascular Disease in Patients with Type 2 Diabetes (2022 Edition)
01 Epidemiological status of panvascular disease in patients with T2DM
02 Pathophysiology of panvascular disease in patients with T2DM
03 Multidisciplinary collaborative diagnosis and treatment of panvascular disease in patients with T2DM
04 Risk assessment of panvascular disease in patients with T2DM
05 Management strategies for panvascular disease in patients with T2DM
The consensus highlights the content of early risk assessment of panvascular disease in T2DM patients, that is, the assessment of risk factors, vascular structure and function and target organ damage is carried out at least once a year, and emphasizes that the management of panvascular disease in T2DM patients needs to be jointly participated by patients and multidisciplinary physicians, and the control of blood glucose, blood pressure, blood lipids and antiplatelet therapy
are strengthened on the basis of lifestyle intervention.
This article shares
with you the important content of panvascular disease risk assessment in patients with type 2 diabetes.
Risk assessment of panvascular disease in patients with T2DM
Patients with T2DM are routinely consulted, physical examination and general laboratory tests, such as urine routine, liver function, kidney function, blood glucose, glycated hemoglobin (HbA1c), insulin, C peptide, etc.
, and a systematic panvascular disease risk assessment (Table 1) is also carried out to detect subclinical atherosclerosis and target organ damage
early.
recommend
The systematic assessment of panvascular disease in patients with T2DM includes at least risk factors, vascular structure and function, and target organ damage
.
Table 1.
Content of panvascular disease risk assessment in patients with T2DM
Management strategies for panvascular disease in patients with T2DM
The consensus also clarifies the importance of biomarkers in the management of panvascular disease in T2DM patients, and recommends that myocardial markers (NT-proBNP, hs-cTnT), lipid profile and renal function indicators be evaluated at least once a year at the time of diagnosis and subsequent follow-up of
T2DM patients.
➤Application value of myocardial markers in the risk assessment and management of panvascular disease in T2DM patients
NT-proBNP：
For every 100 pg/mL increase in NT-proBNP, the 5-year hospitalization rate for cardiovascular events increased by 12%
in patients with T2DM.
Intensive cardioprotective therapy in patients with T2DM with NT-proBNP>125 pg/mL reduced the risk of hospitalization or death from cardiovascular disease by 65% after 2 years
.
hs-cTnT:
hs-cTnT is a specific and highly sensitive marker of myocardial injury that reflects chronic subclinical myocardial injury
in patients with T2DM.
Patients with T2DM have a significantly higher risk of elevated hs-cTnT (≥14 ng/L) than non-diabetic people, and the relative risk of coronary heart disease, heart failure, and all-cause mortality is also significantly increased
over the next 5 years.
recommend
Patients with T2DM are assessed at least once a year at diagnosis and at least one subsequent follow-up with NT-proBNP/BNP and hs-cTn
.
If NT-proBNP>125 pg/mL or BNP>50 pg/mL or hs-cTn is found to exceed the upper limit of the reference value, or if NT-proBNP/BNP or hs-cTn is elevated through serial monitoring, cardioprotective therapy should be initiated immediately with increased frequency
of follow-up.
➤Application value of lipid profiling in the risk assessment and management of panvascular disease in T2DM patients
recommend
At least one blood lipid profile, including total cholesterol, TG, LDL-C, HDL-C, and ApoB, was assessed at the time of diagnosis and subsequent follow-up in patients with T2DM; Lp(a) levels are measured at least once in patients with T2DM after diagnosis; LDL-C, non-HDL-C, and ApoB are the main targets for diagnosis and treatment
.
➤The application value of renal function indicators in the risk assessment and management of panvascular disease in T2DM patients
urine albumin/creatinine ratio:
Urinary albumin excretion can be reflected by UACR (urine albumin/creatinine ratio), and UACR≥ 30mg/g is positive;
serum creatinine:
Used to calculate the estimated glomerular filtration rate (eGFR).
recommend
➤ UACR and serum creatinine
are assessed at least once a year at the time of diagnosis and subsequent follow-up in patients with T2DM.
➤After the diagnosis of DKD is confirmed in patients with T2DM, the stage of CKD should be further judged according to the eGFR and urine albumin levels, the risk of DKD progression should be assessed, and the frequency of
evaluation should be clarified.
Note: T2DM is type 2 diabetes; NT-proBNP/BNP is N-terminus-B natriuretic peptide/B-type natriuretic peptide; hs-cTnT is highly sensitive cardiac troponin T; TG is triglycerides, LDL-C is LDL cholesterol, HDL-C is HDL cholesterol, and ApoB is apolipoprotein B; UACR is the urine albumin/creatinine ratio; CKD is chronic kidney disease; DKD is diabetic nephropathy
.
Source:
1.
Chinese Medical Doctor Association Cardiovascular Medicine Branch, Expert Group of "Chinese Expert Consensus on Risk Assessment and Management of Panvascular Disease in Patients with Type 2 Diabetes".
Expert consensus on risk assessment and management of panvascular disease in patients with type 2 diabetes mellitus (2022 edition)[J].
Chinese Journal of Diabetes,2022,14(10):1017-1034.
2.
Cardiovascular Medicine Branch of Chinese Medical Doctor Association, Expert Group of "Chinese Expert Consensus on Risk Assessment and Management of Panvascular Disease in Patients with Type 2 Diabetes".
Expert consensus on risk assessment and management of panvascular disease in patients with type 2 diabetes mellitus (2022 edition)[J].
Chinese Journal of Health Management,2022,16(10):673-689.
